FSD Pharma Inc. (HUGE)

FSD Pharma Income Statement

Financials in millions CAD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	8.24	9.03	14.45	15.93	10.06	8.41
Research & Development	1.71	3.86	6.91	6.33	7.83	0
Other Operating Expenses	6.26	10.9	6.07	11.49	12.8	14.08
Operating Expenses	16.2	23.79	27.43	33.74	30.69	22.48
Operating Income	-16.2	-23.79	-27.43	-33.74	-30.69	-22.48
Interest Expense / Income	0.01	0	0.05	0.07	0.24	0.16
Other Expense / Income	-6.37	-5.89	-3.87	1.47	0.87	16.49
Pretax Income	-9.85	-17.9	-23.61	-35.29	-31.8	-39.13
Net Income	-9.85	-17.9	-23.61	-35.29	-31.8	-39.13
Shares Outstanding (Basic)	40	40	39	35	12	7
Shares Outstanding (Diluted)	40	40	39	35	12	7
Shares Change	1.77%	2.21%	10.84%	190.15%	70.69%	19.49%
EPS (Basic)	-0.26	-0.46	-0.61	-1.01	-2.64	-5.55
EPS (Diluted)	-0.26	-0.46	-0.61	-1.01	-2.64	-5.55
Free Cash Flow	-8.05	-10.83	-28.7	-21.25	-19.13	-14.01
Free Cash Flow Per Share	-0.20	-0.27	-0.74	-0.61	-1.59	-1.99
EBITDA	-8.34	-15.4	-19.02	-31.17	-27.66	-37.03
Depreciation & Amortization	1.5	2.51	4.53	4.05	3.9	1.94
EBIT	-9.84	-17.9	-23.56	-35.22	-31.56	-38.97

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).